MedTrace Logo

Long-term Study of DSP-5423P in Patients With Schizophrenia

NCT02335658 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-04-12

Study results available
· View outcomes & findings →

Summary

The study evaluates the long term safety of DSP-5423P in patients with schizophrenia.

Conditions

Interventions

DRUG

DSP-5423P

40-80mg/day

Sponsors & Collaborators

  • Sumitomo Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Director, Drug Development Division · Sumitomo Pharma Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02335658 on ClinicalTrials.gov